BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:BLC - FR0000035370 - Common Stock
24 EUR
-0.4 (-1.64%)
Overall BLC gets a fundamental rating of 4 out of 10. We evaluated BLC against 28 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of BLC while its profitability can be described as average. BLC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
BLC had a positive operating cash flow in the past year.
Of the past 5 years BLC 4 years were profitable.
BLC had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BLC has a Return On Assets of 0.08%. This is in the lower half of the industry: BLC underperforms 75.00% of its industry peers.
Looking at the Return On Equity, with a value of 0.74%, BLC is doing worse than 71.43% of the companies in the same industry.
BLC has a Return On Invested Capital of 6.37%. This is in the better half of the industry: BLC outperforms 60.71% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BLC is in line with the industry average of 6.91%.
The 3 year average ROIC (6.13%) for BLC is below the current ROIC(6.37%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROIC | 6.37% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.22%
ROIC(3y)6.13%
ROIC(5y)5.72%
1.3 Margins
With a Profit Margin value of 0.11%, BLC is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
BLC's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 8.14%, BLC is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
With a decent Gross Margin value of 67.80%, BLC is doing good in the industry, outperforming 78.57% of the companies in the same industry.
BLC's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.14% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.34%
OM growth 5Y0.66%
PM growth 3Y-66.7%
PM growth 5Y-48.68%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
BLC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, BLC has about the same amount of shares outstanding.
Compared to 5 years ago, BLC has about the same amount of shares outstanding.
BLC has a better debt/assets ratio than last year.
2.2 Solvency
BLC has an Altman-Z score of 1.39. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BLC (1.39) is worse than 64.29% of its industry peers.
The Debt to FCF ratio of BLC is 12.84, which is on the high side as it means it would take BLC, 12.84 years of fcf income to pay off all of its debts.
BLC has a Debt to FCF ratio (12.84) which is in line with its industry peers.
BLC has a Debt/Equity ratio of 5.31. This is a high value indicating a heavy dependency on external financing.
BLC's Debt to Equity ratio of 5.31 is on the low side compared to the rest of the industry. BLC is outperformed by 85.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.31 | ||
| Debt/FCF | 12.84 | ||
| Altman-Z | 1.39 |
ROIC/WACC1.27
WACC5%
2.3 Liquidity
A Current Ratio of 1.39 indicates that BLC should not have too much problems paying its short term obligations.
With a decent Current ratio value of 1.39, BLC is doing good in the industry, outperforming 71.43% of the companies in the same industry.
A Quick Ratio of 1.19 indicates that BLC should not have too much problems paying its short term obligations.
BLC has a Quick ratio of 1.19. This is in the better half of the industry: BLC outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 158.33% over the past year.
BLC shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.37% yearly.
The Revenue has been growing slightly by 6.35% in the past year.
Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
BLC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.18% yearly.
BLC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.69% yearly.
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 342.86, the valuation of BLC can be described as expensive.
BLC's Price/Earnings ratio is a bit more expensive when compared to the industry. BLC is more expensive than 75.00% of the companies in the same industry.
BLC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.51.
The Price/Forward Earnings ratio is 9.60, which indicates a very decent valuation of BLC.
Based on the Price/Forward Earnings ratio, BLC is valued cheaply inside the industry as 89.29% of the companies are valued more expensively.
BLC is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 342.86 | ||
| Fwd PE | 9.6 |
4.2 Price Multiples
BLC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BLC is cheaper than 89.29% of the companies in the same industry.
BLC's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BLC is cheaper than 78.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.53 | ||
| EV/EBITDA | 5.58 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)18.05
PEG (5Y)N/A
EPS Next 2Y0.72%
EPS Next 3Y6.18%
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:BLC (12/31/2025, 7:00:00 PM)
24
-0.4 (-1.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.78%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap176.88M
Revenue(TTM)491.18M
Net Income(TTM)530.00K
Analysts83.33
Price Target36.72 (53%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP107.55%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.5%
EPS NY rev (3m)-4.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 342.86 | ||
| Fwd PE | 9.6 | ||
| P/S | 0.36 | ||
| P/FCF | 5.53 | ||
| P/OCF | 1.92 | ||
| P/B | 2.46 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.58 |
EPS(TTM)0.07
EY0.29%
EPS(NY)2.5
Fwd EY10.42%
FCF(TTM)4.34
FCFY18.09%
OCF(TTM)12.48
OCFY52.01%
SpS66.65
BVpS9.77
TBVpS-16.27
PEG (NY)18.05
PEG (5Y)N/A
Graham Number3.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROCE | 8.67% | ||
| ROIC | 6.37% | ||
| ROICexc | 6.75% | ||
| ROICexgc | 12.06% | ||
| OM | 8.14% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.51% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.22%
ROIC(3y)6.13%
ROIC(5y)5.72%
ROICexc(3y)6.56%
ROICexc(5y)6.11%
ROICexgc(3y)13.97%
ROICexgc(5y)12.75%
ROCE(3y)8.35%
ROCE(5y)7.8%
ROICexgc growth 3Y2.87%
ROICexgc growth 5Y-0.99%
ROICexc growth 3Y7.59%
ROICexc growth 5Y0.26%
OM growth 3Y5.34%
OM growth 5Y0.66%
PM growth 3Y-66.7%
PM growth 5Y-48.68%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score7
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.31 | ||
| Debt/FCF | 12.84 | ||
| Debt/EBITDA | 3.78 | ||
| Cap/Depr | 98.36% | ||
| Cap/Sales | 12.22% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.12% | ||
| Profit Quality | 6037.74% | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 1.39 |
F-Score7
WACC5%
ROIC/WACC1.27
Cap/Depr(3y)93.08%
Cap/Depr(5y)92.09%
Cap/Sales(3y)11.16%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
EBIT growth 1Y17.78%
EBIT growth 3Y7.03%
EBIT growth 5Y5.81%
EBIT Next Year137.78%
EBIT Next 3Y39.06%
EBIT Next 5YN/A
FCF growth 1Y1.88%
FCF growth 3Y107.42%
FCF growth 5Y33.53%
OCF growth 1Y13.78%
OCF growth 3Y17.4%
OCF growth 5Y14.22%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a valuation rating of 4 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the expected EPS growth for BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The Earnings per Share (EPS) of BASTIDE LE CONFORT MEDICAL (BLC.PA) is expected to grow by 18.99% in the next year.
Can you provide the dividend sustainability for BLC stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 107.55%.